AI Insight
Researchers developed a dual-threshold model for the pancreatic cancer biomarker CA19-9, which incorporates both an upper and a lower cutoff value. This approach addresses a known limitation of standard CA19-9 testing: some patients carry a genetic variant that prevents them from producing this antigen, causing their levels to remain artificially low even when they have advanced disease. By flagging these very low readings as a separate risk category, the model can identify high-risk pancreatic cancer cases that would otherwise be missed.
Why it matters
Pancreatic cancer is frequently diagnosed at a late stage due to inadequate early detection tools, and improving the interpretation of existing biomarkers like CA19-9 could help clinicians catch more high-risk cases sooner without requiring new laboratory infrastructure.
A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.
Source: Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer